Search
for

    GlossaryRuxolitinib

    medication that inhibits JAK enzymes to treat certain diseases

    Ruxolitinib, also known by the brand name Jakafi, is a medication that inhibits Janus kinase (JAK) enzymes, which are involved in the signaling pathways that regulate immune function and blood cell production. It is primarily used to treat conditions like myelofibrosis and polycythemia vera, and has shown promise in treating certain types of alopecia by modulating the immune response that attacks hair follicles.

    Related Terms

    Sort by

    Learn

    5 / 801 results

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

      learn Baricitinib

      JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen
    Next page →